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Key points: 
 
There is a variation in platelet function between normal individuals and this function is consistent within the 
same individual over time. 
 
The data from this study suggest that variation in donor platelet function does not affect the outcome of 
prophylactic transfusion. 
 
Abstract  
The effect of variation in platelet function in platelet donors on patient outcome following platelet transfusion is 
unknown. This trial assessed the hypothesis that platelets collected from donors with highly responsive platelets 
to agonists in vitro assessed by flow cytometry (high responder donors), are cleared more quickly from the 
circulation than those from low responder donors, resulting in lower platelet count increments following 
transfusion. 
This parallel group, semi-randomised double-blinded trial was conducted in a single UK centre. Eligible patients 
were those 16 or older with thrombocytopenia secondary to bone marrow failure, requiring prophylactic platelet 
transfusion.  Patients were randomly assigned to receive a platelet donation from a high or low responder donor 
when both were available, or when only one type of platelet was available patients received that. Participants, 
investigators and those assessing outcomes were masked to group assignment. The primary endpoint was the 
platelet count increment 10-90 minutes following transfusion. Analysis was by intention-to-treat.  
Fifty one patients were assigned to receive platelets from low responder donors, and 49 from high responder 
donors (47 of which were randomised and 53 non-randomised). There was no significant difference in platelet 
count increment 10-90 minutes following transfusion in patients receiving platelets from high (mean 21.0 
x109/L, 95% CI 4.9 to 37.2) or low (mean 23.3x109/L, 95% CI 7.8 to 38.9) responder donors (mean difference 
2.3, 95%CI -1.1 to 5.7, p = 0.18).  
These results support the current policy of not selecting platelet donors on the basis of platelet function for 
prophylactic platelet transfusion.  
Keywords 
Platelet, transfusion, platelet concentrate, platelet function, bleeding, count increment, randomised controlled 
trial 
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Introduction 
Most platelets are transfused prophylactically, on the basis of platelet count, to reduce the risk of bleeding in 
patients who have developed thrombocytopenia as a result of treatment for haematological malignancies 1. 
Blood Services ensure the safety and efficacy of platelets for transfusion through validation of new processes for 
their collection, production and storage, and compliance with regulatory standards. However, little attention has 
been paid to the effect of donor-related variation in the donated material on patient outcomes. This is 
particularly relevant to platelets collected by apheresis (derived from single donors), where platelet dysfunction 
in the donor will have a larger effect than those derived from a pool of four or more whole blood donations. 
Unlike drugs, that can be produced to uniform potency, the composition of platelet concentrates for the 
prevention or treatment of bleeding varies, mainly due to natural variation in haematological traits between 
donors. Platelet function is highly variable between individuals, but for a given individual is highly consistent 
over time 2. These observations together with those in twins 3, suggests that platelet function is to a large extent 
a heritable trait. Consequently, there is great interest in how such variation may relate to an individual’s risk of 
thrombosis or bleeding and in tailoring of pharmacological interventions to reduce this risk. We have shown that 
inherent variation in platelet responsiveness to agonists assessed by flow cytometry is to a large extent 
genetically controlled, by employing methods that assess two well characterised but distinct platelet signalling 
pathways known to be important in platelet activation after atherosclerotic plaque rupture, and that provide 
information on both platelet receptor activation and degranulation 4. We have identified 24 genes that show an 
association between platelet responsiveness and sequence variation and demonstrated that platelet 
responsiveness of a donor at the extremes of the distribution of responses (high or low) is reproducible over time 
4,5 and that donors with highly responsive platelets are more likely to produce a unit of platelets containing a 
higher level of activated platelets 6.  
Whether increased activation that occurs during storage of platelets reduces platelet survival once transfused is 
unclear. Data from animals models is mixed – some suggest that platelet activation is related to platelet 
clearance 7 whereas others suggest that this is not the case 8,9. In humans, several studies have suggested that 
increased platelet activation in platelet concentrates might be associated with reduced survival following 
infusion to healthy subjects 10,11, whereas others have failed to observe such a relationship 12.  
There is increasing evidence to suggest that phenotypic and proteomic changes that occur during the storage of 
red cells and platelets for transfusion may in part be determined by the genotype of the donor13–15. These 
observations and others have led to an increased international focus on the role of the donor in the quality of red 
cells and platelets for transfusion. Reduced costs and ease of genotyping now make large scale testing of donors 
a reality. It is therefore important to understand whether genetic variation in platelet function at the point of 
donation and/or on subsequent storage translates into clinically relevant outcomes for recipients of platelets. 
This is the first study in the literature to examine this question. 
We conducted a trial in patients receiving platelets for prophylaxis to assess whether differences in platelet 
function in the donor population affect the clinical outcome from platelet transfusion. To maximise the 
likelihood of observing a difference between groups, we selected donors with platelet responsiveness at the 
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extreme ends of the distribution (high or low responders). We hypothesised that platelets derived from high 
responder donors would be cleared more rapidly from the circulation than those from low responder donors, 
leading to lower platelet count increments following transfusion, and potentially a shortening of the time until 
the next platelet transfusion was required.   
 
Methods 
Study design 
We conducted a parallel-group, double-blinded, semi-randomised trial at a single centre in the UK - the Platelet 
Responsiveness and Outcome from Platelet Transfusion (PROmPT) trial. Patients were randomised to receive a 
single platelet transfusion from either a high or low responder donor. Since it was possible that platelets from 
high or low responder donors may not differ from each other, but that either might differ from those from 
donors of average responsiveness, we concurrently enrolled a group of 30 patients that received platelets from 
unselected donors for comparison (referred to as unselected units). Participants, treating clinicians, those 
assessing outcomes and analysing data were blinded to treatment group throughout. Randomisation was 
performed using unstratified permuted blocks via an on-line randomisation service (www.sealedenvelope.com) 
by randomisation coordinators who were not part of the trial personnel involved in the enrolment, treatment or 
measurement of outcomes.  The protocol included a pre-specified interim analysis after 20 patients presented for 
randomisation, as we predicted that insufficient platelet availability might result in an unacceptably low 
percentage of enrolled patients being randomised. The study protocol specified that in such circumstances an 
alternative treatment allocation procedure would be followed, resulting in a semi-randomised study: when donor 
platelet units from both high and low responders were available, patients would be randomised to receive either, 
but if only one type of platelet unit were available (i.e. from either a high or low responder) the patient would 
receive that unit (non-randomised). Although the allocation was not randomised in this circumstance, blinding 
was maintained. If neither were available then patients received a suitable platelet unit from an unselected 
donor. The full study protocol is publically available 16.  
Participants 
a) Donors 
We previously established a cohort of 506 donors whose platelets were tested by flow cytometry for 
responsiveness to two agonists (collagen-related peptide-XL or ADP) each with two measures of response 
(fibrinogen binding or P-selectin expression) resulting in four endpoints 4. To provide sufficient donors for this 
study we increased this cohort to 956 by testing an additional 450 donors using the same methods. To determine 
the platelet responsiveness phenotype, the percentage positive (PP) platelets for each of the four endpoints was 
transformed to the logit scale, that is, log(PP/(100-PP)) and then a multiple linear regression model applied with 
the date of sample testing as a continuous predictor. To combine the data into one overall measure of platelet 
response and thus assign the donor to a high or low category, the data from each of the four endpoints was 
transformed so that the data from each output occupied the same range and distribution as described previously 
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4. The standardised residual from the regression model was used to rank how far an individual donor deviated 
from the average response.  High responders were defined as those with the highest minimum response and low 
responders as those with the lowest maximum of all four endpoints. Those donors with the most reproducible 
responses in the upper and lower 10% of the distribution were selected to form a panel of donors for the study 
(26 high responder and 19 low responder donors). An example of donor selection can be found in the 
supplementary material. 
 The testing of donors was approved by the Huntingdon Research Ethics Committee (Reference 05/Q0104/27). 
b) Patients 
Eligible patients, aged 16 years or above, were stable haematology patients requiring platelets for prophylactic 
transfusion. Both in patients and outpatients were recruited, diagnoses included acute leukaemia, bone marrow 
failure and both autologous and allogenic transplant. Exclusion criteria included patients with inherited or 
acquired coagulation or platelet function disorders, current acute promyelocytic leukaemia or other active 
malignancy in past 5 years (other than the current primary diagnosis), previously documented WHO Grade 4 
bleeding, palpable splenomegaly, were pregnant or lactating, immunological refractoriness to platelet 
transfusion or those requiring HLA or HPA matched platelets. Patients were temporarily excluded from the trial 
for factors such as fever, that might influence the primary and secondary endpoints measured (see 
supplementary information). Once resolved, patients with temporary exclusion criteria were eligible for 
inclusion. Patients were eligible to receive a single transfusion from both an unselected donor and either one 
high or low-responder donor in the course of their treatment, but only once the follow-up period from their 
previous trial transfusion was complete (5 days or until their next platelet transfusion).  
Approval for the study was granted from the Hertfordshire Research Ethics Committee (Reference 11/EE/0227). 
Procedures 
Donors for the study fulfilled all requirements for platelet donation according to national guidelines17 . 
Leucocyte-depleted platelets were collected by apheresis using a single type of collection device for the entire 
study duration (Trima Accel, Terumo BCT, Lakewood, Co, USA) and stored in plasma for up to 5 days from 
donation. Patients that were likely to become thrombocytopenic and require a prophylactic platelet transfusion 
were enrolled by their clinical care team. The decision to transfuse was made by the clinician caring for the 
patient, usually when the platelet count fell below 10 x109/L according to local and national guidelines. Patients 
received a single unit of platelets and were followed up for 5 days or until their next platelet transfusion. 
Platelets were matched for ABO and RhD blood group according to local guidelines. The threshold for red cell 
transfusion in the absence of bleeding was 90g/L haemoglobin. Blood samples were taken on the day of 
transfusion, and 10-90 minutes and 12-36 hours after transfusion. A full blood count was made on samples 
anticoagulated with EDTA using a haematology analyser to measure platelet count (LH750, Beckman Coulter, 
High Wycombe, UK). Bleeding symptoms were recorded on the day of transfusion and daily thereafter by the 
clinical team and by validated patient self-assessment 18. Clinician and patient self-assessment were made for 
days when patients were in hospital, but patient self-assessment only for periods of follow up when patients 
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were at home. Bleeding was graded according to a modified WHO system by the use of a computer generated 
algorithm. In this, the most commonly used method of assessing bleeding in platelet transfusion trials, bleeding 
is categorised as grade 1 (mild), grade 2 (moderate, not usually requiring red cells transfusion), grade 3 (severe, 
requiring red cell transfusion) and grade 4 (debilitating or life-threatening). In accordance with a recent trial of 
platelet transfusion that required assessment of bleeding19, two types of grade 1 bleeding (spreading or 
generalised petechiae or a nose bleed lasting more than 30 minutes) were classified as grade 2 for this study 
since these may be considered clinically significant in patients with thrombocytopenia and regarded by many 
treating clinicians as a trigger for platelet transfusion. 
Outcomes 
The primary outcome was the platelet count increment (CI) 1 hour (10-90 minutes) following transfusion, i.e. 
the difference between platelet count before and after transfusion. Secondary outcomes were the platelet CI at 
24 hours (12-36 hours); the corrected count increment (CCI) at 1 hour (10-90 minutes) and 24 hours (12-36 
hours); number of patients with at least one WHO bleeding event grade 2,3 or 4 within the follow up period; 
number of days with WHO bleeding events grade 2,3 or 4 within the follow up period; number of red cell 
transfusions within the follow up period and time to next platelet transfusion. The CCI was defined as (CI x 
body surface area)/ platelet dose (x1011). Bleeding assessed by study clinician or patient self-assessment were 
considered as separate outcomes. Data on adverse events were collected according to standard definitions used 
in the UK Serious Hazards of Transfusion Haemovigilance scheme. Events which were judged to be expected 
and as a result of the patient’s underlying diagnosis were not reported as serious adverse events (SAEs) but were 
logged as adverse events. The rationale for choice of endpoints can be found in the full study protocol 16.  
Statistical Analysis 
The required sample size was calculated based on the difference in the platelet count increment (primary 
outcome) following transfusion between patients receiving platelets from high or low responder donors. Interim 
data from another clinical study of platelets ongoing in our organisation at the time and since reported for the 
same measure 20 gave a standard deviation of 11.5x109/L (at 12-36 hours, from 65 patients and 95 transfusions). 
Based on 80% power, a 5% significance level, and a presumed 10% dropout rate, 100 patients (50 in each 
group) would be required to detect a mean difference of 7x109/L between the two groups.  
A secondary set of analyses included patients who received units from unselected donors, in order to assess 
whether units from high or low responder donors differed to those from donors not at the extremes of the 
distribution. Recruiting 30 patients who received platelets from unselected donors allowed calculation of a 95% 
confidence interval for the difference in platelet increments between a treatment group and the unselected group 
to within +/-2.5 (i.e. the width of the confidence interval will be 5). As some of the patients that received a 
transfusion from an unselected donor also received a transfusion from a high or low-responder donor, this also 
increased the precision of estimates. 
All analyses were by intention-to-treat and all patients allocated to receive a trial unit were included in the 
analysis, regardless of whether they were randomised to receive that unit, or not except for two patients in the 
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unselected group who received a pooled platelet concentrate rather than apheresis and were excluded from 
analysis. Analyses were two-sided, and the significance level was 5%. Platelet count increments at 1 and 24 
hours were analysed using a mixed-effects linear regression model with a treatment-time interaction. In order to 
increase power, the model was adjusted for body surface area, platelet dose, and age of platelet unit, factors 
known to affect these outcomes. All patients with an observed platelet count increment at either 1 or 24 hours 
were included in the analysis. Further details of the regression models used can be found in the supplementary 
materials and methods for dealing with missing data are given in the study Statistical Analysis Plan 21.  
An independent data monitoring committee reviewed patient safety and the results of the interim data analysis. 
The study was adopted by the National Cancer Research Network and included in the UK NIHR Clinical 
Research Network Portfolio. Due to a change in trial managers in the run-up to trial commencement, and the 
reminders to register the trial being sent to an obsolete email account, the trial was registered on the ISCTRN 
database (ISRCTN56366401) about half way through recruitment [first patient enrolled October 2011, trial 
registered November 2012, last patient enrolled December 2013].  
 
Results 
The interim analysis took place after 21 patients had presented for randomisation, of which only 9 had been 
successfully randomised, predominantly due to insufficient supply of trial units. Therefore, as pre-specified in 
the protocol, the study became semi-randomised at that point.  
Of 428 patients screened, 252 consented to be part of the study (Figure 1). Of the 252 patients consented, 137 
were not allocated to receive a transfusion as there was either no suitable platelet unit available or the patient 
had a temporary exclusion criterion. One hundred patients were allocated to receive a trial unit: 49 from a high 
responder donor (23 randomised, 26 non-randomised) and 51 from a low responder donor (24 randomised, 27 
non-randomised). One patient due to receive platelets from a donor in the low responder group withdrew 
consent prior to transfusion. Therefore, 49/49 patients in the high responder group and 50/51 in the low 
responder group received their allocated trial unit. Thirty patients consented and were assigned to receive a 
transfusion from an unselected donor. Two of the 30 patients received a pooled platelet concentrate rather than 
apheresis and were excluded from analysis. In total, 15 patients received a transfusion from both an unselected 
donor and either a high or low-responder donor.  
Baseline characteristics were well matched between study groups (Table 1). Platelets for the trial were derived 
from 15 high responder and 16 low responder donors. Platelet units that were ABO identical to that of the donor 
were received by 96% of patients, and 98% of trial units transfused were irradiated. All RhD negative patients 
received RhD negative units.  
The platelet count increment at 1 hour (the primary endpoint) was available for 90% of patients in the low 
responder group and 100% of patients in the high responder group. For the 24 hour platelet count increment, 
these values were 90% and 96% respectively. Assessment of bleeding symptoms by a clinician was made for 
94% of patients in the low responder group and 90% in the high responder group, and by patient self-assessment 
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for 92% and 94% of patients respectively. Data on red cell transfusions and time to next platelet transfusion 
were collected on 100% of patients.  
Results are shown in Tables 2 and 3. There was no significant difference between patients receiving platelets 
from high or low responder donors in either the 1 hour platelet count increment (primary endpoint) (low 
responder 23.3x109/L versus high responder 21.04; difference 2.30, 95%CI -1.09 to 5.69, p = 0.18), or the 24 
hour platelet count increment (high responder 12.90 versus low responder 14.31x109/L; difference 1.41, 95% CI 
-1.96, 4.78, p = 0.41). There was also no significant difference between groups in corrected count increments at 
1 or 24 hours.  
There were no significant differences in any bleeding outcome between patients receiving platelets from high or 
low responder donors, including clinician assessed bleeding scores (odds ratio 0.78, 95% confidence interval 
0.29-2.16, p=0.64) and number of days with a Grade 2-4 bleed (rate ratio was 0.70, 95% confidence interval 
0.16 to 2.97, p = 0.63), Table 3. In addition, there was no significant difference in any of the outcomes measured 
between high or low responder groups and patients that received platelets from unselected donors (Tables 2 & 
3). 
There was one febrile transfusion reaction reported in the low responder arm of the trial. This was initially 
reported as a SAE, but on further analysis did not meet criteria as the patient recovered rapidly with no 
increased duration of hospitalisation. There were no other SAEs.  
 
Discussion 
In the first controlled trial to assess whether differences in the level of platelet responsiveness in the donor 
population affect clinical outcome, we have shown that the outcome from prophylactic platelet transfusion in 
haematology patients does not differ whether the donor of the platelets has very low or highly responsive 
platelets to agonists in vitro.  
The results from our study add to those conducted in healthy subjects and suggest that the ability of platelets to 
survive in the circulation following transfusion to patients is not related to how responsive the platelets of the 
donor are. Since the main indication to transfuse platelets is to prevent bleeding, and there is a poor correlation 
between bleeding risk and platelet count increments in thrombocytopenic patients we also assessed bleeding 
according to the WHO grading system, the most commonly used method of assessing bleeding in platelet 
transfusion trials. We also collected data on the number of red cell transfusions and time to next platelet 
transfusion as surrogates for bleeding. There was no significant difference between groups in any of these 
endpoints. Although the study was not powered with bleeding as the primary endpoint, these data indicate that 
in addition to there being no difference in the survival of platelets following transfusion between groups, the 
ability of platelets to prevent bleeding was also not different. The percentage of patients experiencing grade 2 or 
higher bleeding symptoms was lower in this study (18-25%) compared with other recent prophylactic platelet 
trials such as TOPPS (43%) and PLADO (70%). We attribute this to the strict exclusion criteria in this study, 
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especially temporary deferral for fever, and because patients were only studied for one platelet transfusion. 
Only two other clinical studies have attempted to address whether differences in the functionality of platelets 
might influence outcome from platelet transfusion. An observational study measuring levels of P-selectin, a 
marker of platelet activation, in platelet concentrates suggested that lower 1 hour count increments were 
observed with increasing levels of platelet activation 22. However, the study was too small (eight patients) to 
draw any conclusions. In another observational study, transfusions to 40 children were retrospectively 
categorised into two groups (high and low) based on the immature platelet fraction (IPF) of the platelet 
concentrate transfused 23. The IPF is a parameter reported by some haematology analysers that indicates the 
proportion of platelets that are reticulocytes, those platelets most recently formed 24. Those receiving platelets 
from the ‘high’ group received fewer platelet transfusions, and had fewer bleeding episodes, although the 
method of assessing bleeding in the study is unclear. In our study we observed a higher IPF in the whole blood 
of high-responder donors, but following transfusion there was no difference in the IPF measured between 
patients receiving platelets from high or low-responder donors (data not shown). This discrepancy could be due 
to preferential removal of sub-populations of platelets by either the apheresis device or transfusion set. 
The data from our study are intriguing, indicating that differences identified by laboratory testing of measures 
such as platelet responsiveness in platelet donors prior to donation do not translate to differences in clinical 
outcome from platelet transfusion. It is therefore essential that major changes to platelet production that might 
affect their function undergo clinical assessment prior to introduction, rather than rely solely on laboratory data. 
In addition, there is insufficient evidence to recommend that platelet donors be selected on the basis of platelet 
function. Therefore, our data support the current policy employed by blood services internationally of not 
assessing platelet function in apheresis donors prior to donation.  
The strengths of our study include the high level of adherence to protocol and little loss to follow up or missing 
data. Although approximately 50% of patients were not randomised, the number of transfusions from high or 
low responder donors was almost equal, the baseline characteristics of patients between groups were similar, 
and the blinding of the study meant that study personnel could not bias outcomes between groups. Limitations 
of our study include that patients received a single trial transfusion only. Data from trials of pathogen 
inactivated platelets have shown that differences between control and treated units are more pronounced with 
increasing number of platelet transfusions 25 and we therefore cannot exclude that differences between groups in 
our study may have been observed if patients received multiple transfusions. We also cannot exclude the 
potential influence of previous non-trial transfusions on the outcomes measured. 
An important limitation to the generalisability of our data are that we assessed stable non-bleeding patients 
requiring platelets for prophylaxis. We cannot extrapolate these data to patients actively bleeding at the time of 
transfusion, where the immediate haemostatic effectiveness of platelets might be more important than the ability 
to remain in the circulation. It is conceivable that platelets from high responder donors could be the product of 
choice for bleeding patients, but this can only be elucidated by further research. The role of genetic factors in 
determining aspects of platelet function that may be important in disease states as well as platelet storage and 
the outcome from transfusion warrants further study. 
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Table 1 – Baseline characteristics patients  
Phenotype of platelet donor 
 
Unselected 
 (n=28)a 
High responder 
(n=49)b 
Low responder 
(n=51)c 
Age (years) – mean (SD) 52.5 (16.0) 52.2 (16.6) 49.7 (17.8) 
Male – no. (%) 22 (79%) 29 (59%) 27 (53%) 
Body Surface Area – mean (SD) 1.95 (0.20) 1.91 (0.21) 1.89 (0.24) 
AML 10 (36%) 15 (31%) 18 (35%) 
ALL 2 (7%) 3 (6%) 6 (12%) 
CML 0 0 0 
Lymphoma 7 (25%) 14 (29%) 15 (29%) 
Myeloma 5 (18%) 9 (18%) 6 (12%) 
Diagnosis 
– no. (%) 
Other 4 (14%) 8 (16%) 6 (12%) 
Induction 6 (21%) 8 (16%) 9 (18%) 
Consolidation 1 (4%) 2 (4%) 4 (8%) 
Autograft 10 (36%) 16 (33%) 10 (20%) 
Allograft 6 (21%) 8 (16%) 12 (24%) 
Treatment 
plan – no. 
(%) 
Other 5 (18%) 15 (31%) 16 (31%) 
Pre-transfusion platelet count (109/L)– mean (SD) 8.96 (3.81) 9.73 (4.81) 10.51 (5.94) 
Irradiated platelets given – no. (%) 27 (96%) 48 (98%) 50 (98%) 
Volume of platelets transfused (mL) – mean (SD) 176 (13.6) 175 (10.11) 174 (12.42) 
Platelet dose transfused (x109) – mean (SD) 269 (49) 264 (40) 244 (30) 
Platelet dose transfused per body surface area 
(109/m2) – mean (SD) 
140 (32) 142 (27) 130 (19) 
Age of platelets (days) - median (IQR) 4 (4 - 5) 4 (3 - 5) 4 (3 - 5) 
ABO fully matched – no. (%) 26 (93%) 47 (96%) 49 (96%) 
Number of donors* – no. N/A 15 16 
 
 
Values are means with (SD) except for age of platelets (median with IQR).  afor dose transfused (x109 or 109 per BSA) 
n=15, bfor dose transfused (x109 or 109 per BSA) n=44 , cfor pre-transfusion platelet count n=49 and for dose 
transfused (x109 or 109 per BSA) n=48. *The number of donors who have donated platelets transfused to patients.  
There were no significant differences between groups.  
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Table 2. Primary and secondary platelet count increment outcomes  
Outcome 
Phenotype of platelet donor 
Unselected 
(n=28) 
High responder (n=49) Low responder platelets (n=51) 
Difference from 
unselected group 
Difference from 
unselected group 
Difference from high 
responder group 
Platelet increment at 1 hour  
Mean (SE) 24.00 (1.96) 22.96 (1.54) 22.39 (1.25) 
Difference in means (95% CI)  NA -2.20 (-6.15, 1.75)* -0.15 (-4.31, 4.02)* 2.30 (-1.09, 5.69)† 
P-value NA 0.28* 0.95* 0.18† 
Platelet increment at 24 hours 
Mean (SE) 15.61 (1.75) 14.87 (1.42) 13.74 (1.27) 
Difference in means (95% CI) NA -2.06 (-5.72, 1.59)* -0.93 (-4.82, 2.96)* 1.41 (-1.96, 4.78)† 
P-value NA 0.27* 0.64* 0.41† 
CCI at 1 hour  
Mean (SE) 17.13 (1.22) 16.26 (0.84) 17.29 (0.84) 
Difference in means (95% CI) NA -1.46 (-4.13, 1.22)** -0.12 (-2.84, 2.60)** 1.36 (-0.89, 3.61)†† 
P-value NA 0.29** 0.93** 0.24†† 
CCI at 24 hours  
Mean (SE) 11.01 (1.08) 10.51 (0.88) 10.40 (0.86) 
Difference in means (95% CI) NA -1.12 (-3.69, 1.44)** -1.02 (-3.54, 1.49)** 0.13 (-2.18, 2.44)†† 
P-value NA 0.39** 0.43** 0.91
†† 
 
* taken from a linear mixed-effects model on both 1 and 24 hour time-points with the unselected group as 
reference, adjusted for body surface area (BSA), the platelet dose transfused, age of platelets transfused. 
** taken from a linear mixed-effects model on both 1 and 24 hour time-points with the unselected group as 
reference, adjusted for age of platelets transfused. 
† taken from a linear mixed-effects model on both 1 and 24 hour time-points with the high responder group as 
reference, adjusted for BSA, the platelet dose transfused, age of platelets transfused. 
†† taken from a linear mixed-effects model on both 1 and 24 hour time-points with the high responder group as 
reference, adjusted for age of platelets transfused. 
 
Kelly et al  Platelet responsiveness and outcome from transfusion 
 14 
Table 3. Secondary bleeding outcomes 
Outcome 
Phenotype of platelet donor 
Unselected 
(n=28) 
High responder 
(n=49) 
Low responder (n=51) 
Difference from 
unselected group 
Difference from 
unselected group 
Difference from high 
responder group 
Patients with grade 2-4 bleed: clinical 
assessment – no. (%) 
7 (25%) 10 (20%) 9 (18%) 
Odds ratio (95% CI) NA 0.84 (0.28, 2.56) 0.66 (0.21, 2.03) 0.78 (0.29, 2.16) 
P-value NA 0.76 0.47 0.64 
Patients with grade 2-4 bleed: patient 
self-assessment – no. (%) 
8 (29%) 16 (33%) 21 (41%) 
Odds ratio (95% CI) NA 1.27 (0.45, 3.53) 1.92 (0.70, 5.25) 1.51 (0.66, 3.49) 
P-value NA 0.65 0.20 0.33 
Days with grade 2-4 bleed: clinical 
assessment – median (IQR) 
0 (0 - 1) 0 (0 - 0) 0 (0 - 0) 
Rate ratio (95% CI) NA 0.66 (0.13, 3.41) 0.46 (0.09, 2.30) 0.70 (0.16, 2.97) 
P-value NA 0.62 0.34 0.63 
Days with grade 2-4 bleed: patient 
self-assessment – median (IQR) 
0 (0 - 1) 0 (0 - 1) 0 (0 - 1) 
Rate ratio (95% CI) NA 0.86 (0.25, 2.98) 1.05 (0.31, 3.52) 1.26 (0.53, 3.00) 
P-value NA 0.81 0.94 0.60 
Red cell transfusions –no. median 
(IQR) 
0 (0 - 1) 1 (0 - 1) 0 (0 - 1) 
Rate ratio (95% CI) NA 1.27 (0.64, 2.53) 0.78 (0.38, 1.62) 0.60 (0.33, 1.08) 
P-value NA 0.49 0.50 0.09 
Time from randomisation to next 
platelet transfusion (days) – median 
(IQR) 
3 (2 - 3) 3 (2 - 4) 3 (3 - 4) 
Hazard ratio (95% CI) NA 0.85 (0.47, 1.55) 0.68 (0.36, 1.28) 0.81 (0.49, 1.34) 
P-value NA 0.60 0.23 0.42 
Differences in means are high response vs low response. 
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Figure Legends 
 
Figure 1.  Study enrolment and randomisation 
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Figure 1. Study enrolment and randomisation 
 
 
428 Screened 135 Refused
41 did not meet 
eligibility criteria
252 Consented
137 No available 
unit/temporarily 
ineligible
30 unselected unit
30 completed the study 
period*
2 excluded (given 
pooled PC)
28 were included in 
the analysis
Neither high nor low 
available
High or low 
available
High and low 
available
100 patients enrolled
49 assigned to high 
responder group
23 randomised, 26 
non-randomised
51 assigned to low 
responder group
24 randomised, 27 
non-randomised
49/49 received 
allocated 
transfusion
**50/51 received 
allocated 
transfusion
**99/100 patients included in primary analysis of 1 
hour platelet count increment
* 15 patients also received a unit from a high or low responder donor, **One randomised patient withdrew consent prior to transfusion
 
